Sean Parker-Backed ArsenalBio Wants To Create Better Weapons Against Cancer

ArsenalBio, a precision immunotherapy company backed by billionaire Sean Parker, launched Thursday with $85 million from a Series A funding round that closed in July. The company plans to use machine-learning to discover new gene pathways to fight cancer and then use gene editing technology Crispr to create immune cells that are better at battling solid cancer tumors.